Introduction
Increasing age is directly related to an increasing risk of cancer, and older adults comprise the majority of cancer diagnoses in the US [1] . It is estimated that by 2030, nearly 20% of adults in the US will be C 65 years of age, and that the absolute number will double by 2050 [2] . Hematologic malignancies are frequently diagnosed in older adults, and the median age at diagnosis for diseases such as myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and multiple myeloma is C 65 years [1] .
Recently, the need to improve the evidence base for treating older adults with cancer was highlighted by both the Institute of Medicine (IOM) and the American Society of Clinical Oncology (ASCO) [3, 4] . Despite the initiative to increase the inclusion of older adults in clinical trials, there remains a paucity of data regarding the use of potentially inappropriate medications (PIMs) in the supportive management of older adults undergoing chemotherapy. Geriatric impairments are highly prevalent in older adults with hematologic malignancies [5] , and intensive induction therapy can lead to decreases in physical function that may increase the risk for complications such as falls [6, 7] . The use of antihistamines, corticosteroids, and benzodiazepines for the management of chemotherapy-related side effects, although oftentimes necessary, may lead to additional toxicities that could further exacerbate the risk for adverse outcomes. For example, first-generation antihistamines are associated with sedation, cognitive impairment, and falls [8] , which could further increase the risk for complications in older adults with decreased physical function as a result of their chemotherapy treatment.
The American Geriatrics Society (AGS) Beers Criteria for Potentially Inappropriate Medication Use in Older Adults is a widely consulted resource regarding the safety of specific medications for older adults [9] . The AGS Beers Criteria include an explicit list of PIMs that are best avoided or used with caution in older adults as the potential risks of these medications may outweigh the benefits and safer alternatives may exist [9] . The National Comprehensive Cancer Network (NCCN) provides evidence-based guidelines for the treatment and management of patients with cancer [10] , and publishes a collection of chemotherapy templates of standard treatment regimens [11] . In this study, we evaluated the frequency of six specific medications considered PIMs by the AGS Beers Criteria that are included in the NCCN chemotherapy order templates for hematologic malignancies. Our aim was to document the frequency with which these agents are included in standard treatment regimens for hematologic malignancies. The goal of this study was not to advocate for the elimination of PIMs as supportive therapies in older adults undergoing chemotherapy but rather to draw attention to the potential risks associated with these PIMs and to suggest strategies to minimize their toxicity.
Methods
This study included no human subjects and was exempt from human subjects committee review. There were a total of 311 unique chemotherapy order templates for hematologic malignancies published online by the NCCN [11] as of 20 February 2017. Two authors (AZ and TW) reviewed all 311 chemotherapy order templates, as well as the NCCN Guidelines Ò , for Antiemesis Version 2.2015, which was the most current version at the time of review [12] , and extracted information regarding whether each template made specific recommendations regarding the use of firstgeneration antihistamines, benzodiazepines, corticosteroids, H 2 -receptor antagonists, metoclopramide, or antipsychotics as supportive therapy. Corticosteroids included in the template as part of the treatment regimen and not as supportive therapy were not included in the analysis.
These six medications were chosen because they are commonly used as premedications or antiemetics in treatment regimens for hematologic cancers. All six medications are identified as PIMs under Table 2 (''Medications to avoid for many or most older adults'') and Table 3 (''Medications for older adults with specific diseases or syndromes to avoid'') of the 2015 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults list [9] . These six medications are also listed in the NCCN Guidelines Ò for Older Adult Oncology Version 2.2015 as medications commonly used for supportive care that are of concern in older patients [13] . The frequency of the six PIMs evaluated was tabulated by disease type. IBM SPSS Statistics for Windows, version 23, statistical software (IBM Corporation, Armonk, NY, USA) was utilized for descriptive statistics, including frequencies.
Results
A total of 311 unique chemotherapy order templates were reviewed, detailing treatment regimens for 16 types of hematologic cancers (electronic supplementary Table S1 ). Approximately 45% (142 templates) of the chemotherapy order templates recommended the use of at least one of the six PIMs examined within the template. The remainder of the NCCN chemotherapy templates examined referred to the NCCN Guidelines for Antiemesis [12] for recommendations regarding antiemetic prophylaxis and management.
First-Generation Antihistamines
Diphenhydramine was the most common first-generation antihistamine found in the NCCN chemotherapy order templates examined, with 123 chemotherapy templates (39.5%) examined recommending the use of diphenhydramine as supportive therapy. The maximum single dose of diphenhydramine ranged from 50 to 100 mg, and the majority of the templates gave no specific preference for an intravenous versus oral route of administration. Use of diphenhydramine was most common in chemotherapy templates for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma, lymphoplasmacytic lymphoma, and diffuse large B-cell lymphoma (DLBCL). Diphenhydramine was also listed in the NCCN Guidelines for Antiemesis [12] as an option for the management of dystonic reactions to metoclopramide at a dose of 25-50 mg orally or intravenously every 4-6 h.
Benzodiazepines
The most commonly recommended benzodiazepine was lorazepam at a dose and frequency of 0.5-2 mg orally, intravenously, or sublingually every 4-6 h as needed. Only 18 NCCN chemotherapy order templates (5.8%) made specific recommendations regarding the use of benzodiazepines as supportive therapy. The maximum 24-h dose of lorazepam was 12 mg for all 18 templates. Acute promyelocytic leukemia (APL) and primary central nervous system (CNS) lymphoma were the most frequent cancers with templates that recommended the use of a benzodiazepine. Lorazepam was also recommended as an option for breakthrough treatment of chemotherapy-induced nausea/vomiting by the NCCN Guidelines for Antiemesis [12] , at a dose of 0.5-2 mg orally/sublingually/ intravenously every 6 h as needed.
Corticosteroids
Dexamethasone was the most commonly used corticosteroid, with maximum 24-h doses ranging from 4 to 36 mg. Thirty-one NCCN chemotherapy order templates (9.9%) specifically recommended the use of dexamethasone as premedication or for antiemesis management. A majority of the chemotherapy order templates for APL and primary CNS lymphoma made recommendations for the use of dexamethasone as supportive therapy. In APL, 8 of 23 chemotherapy order templates recommended the use of dexamethasone, with 24-h doses ranging from 12 to 20 mg. One template specifically recommended a lower total 24-h dose of 8 mg for patients who were over 70 years of age. In primary CNS lymphoma, 9 of 16 chemotherapy order templates recommended the use of dexamethasone, with 24-h doses ranging from 12 to 16 mg.
Corticosteroids were also included in the NCCN Guidelines for Antiemesis [12] . For intravenous chemotherapeutic agents with low emetic risk, dexamethasone 12 mg orally/intravenously daily is recommended for emesis prevention and can be repeated for multiday doses of chemotherapy. For intravenous chemotherapeutic agents classified as high or moderate emetic risk, dexamethasone 12 or 20 mg daily orally/intravenously prior to and/or at 8 mg orally/intravenously for several days following administration of chemotherapy is recommended, in combination with neurokinin (NK 1 ) receptor antagonists or serotonin (5-HT) 3 -receptor antagonists. Dexamethasone was also recommended for breakthrough chemotherapyinduced nausea/vomiting at a dose of 12 mg orally/intravenously daily.
H 2 -Receptor Antagonists
Twenty of the NCCN chemotherapy order templates examined (6.4%) made specific recommendations regarding the use of H 2 -receptor antagonists as supportive therapy. The highest frequencies were found in APL and primary CNS lymphoma. Additionally, 70 NCCN chemotherapy order templates (22.5%) recommended consideration of an H 2 -receptor antagonist or a proton pump inhibitor as supportive therapy.
Metoclopramide
Five NCCN chemotherapy order templates (1.6%) made specific recommendations for the use of metoclopramide as supportive therapy. The use of metoclopramide was most frequently found in APL, with four templates recommending the use of metoclopramide for antiemesis management. Metoclopramide was also recommended as an option for emesis prevention in low and minimal emetic risk intravenous chemotherapy, as breakthrough treatment for chemotherapy-induced nausea/vomiting, and as emesis prevention in oral chemotherapeutic agents, by the NCCN Guidelines for Antiemesis [12] . The recommended dose was 10-40 mg orally/intravenously daily every 4 or 6 h as needed.
Antipsychotics
No individual NCCN chemotherapy order templates made specific recommendations regarding the use of antipsychotics as supportive therapy; however, the NCCN Guidelines for Antiemesis [12] recommend olanzapine as an option for the prevention of acute and delayed emesis for high or moderate emetic risk chemotherapeutic agents in combination with dexamethasone. The guidelines also list olanzapine as an option for breakthrough treatment of chemotherapy-induced nausea and vomiting at a dose of 10 mg orally daily for 3 days.
Discussion
The NCCN publishes a collection of up-to-date, evidencebased chemotherapy order templates to guide the treatment and management of a variety of solid and hematologic malignancies, and is a commonly utilized resource for practicing oncologists [11] . Our study shows that PIMs are frequently recommended as supportive therapy in the treatment of hematologic malignancies. Almost half (45%) of the NCCN chemotherapy order templates for hematologic malignancies made specific recommendations for the use of PIMs as supportive therapy, and the remainder refer to the NCCN Guidelines for Antiemesis [12] , which also includes the use of PIMs in antiemesis management. Firstgeneration antihistamines and corticosteroids comprised the majority of PIMs that were specifically recommended within the templates, whereas recommendations for metoclopramide, benzodiazepines, and antipsychotics were relatively infrequent.
The goal of this study was not to advocate for elimination of PIMs as supportive therapies in older adults undergoing chemotherapy for hematologic malignancies, nor was it to criticize the recommendations made by the NCCN. Rather, our purpose was to draw attention to the frequency with which PIMs are included as supportive care in chemotherapy regimens used to treat hematologic malignancies, to highlight the potential risks associated with their use, and to suggest strategies to minimize their toxicity. Strategies may include using the lowest effective dose, selecting alternative agents when the risk/benefit ratio for use of a supportive care PIM is too high, and educating patients and caregivers on their potential toxicities. For example, if alternative agents such as NK 1 receptor antagonists or serotonin (5-HT) 3 -receptor antagonists can be used, then these agents should be preferentially considered over agents such as metoclopramide, benzodiazepines, or antipsychotics for emesis prevention [14] as these agents have not been associated with adverse outcomes in older adults [15, 16] . In situations where the use of corticosteroids or diphenhydramine may be necessary, patients and caregivers should be educated regarding the potential side effects and the need for closer monitoring to prevent adverse outcomes such as falls.
PIMs listed by the AGS Beers Criteria are divided into several categories, such as ''medications to avoid for many or most older adults'', ''medications to avoid for older adults with specific diseases or syndromes'', and ''medications to be used with caution''. Table 1 provides a summary of the effects of the six PIMs evaluated in this study, along with recommendations for management to minimize toxicities. First-generation antihistamines such as diphenhydramine are listed under the AGS Beers category of medications to avoid for many or most older adults. Diphenhydramine is associated with sedation and cognitive impairment and should be avoided, especially in older adults with delirium [9] . Diphenhydramine clearance is significantly slower in older adults, which can cause confusion, dry mouth, and constipation [17] [18] [19] . These side effects can worsen delirium and increase the risk of falls and injury [20] . Higher cumulative anticholinergic use has also been associated with an increased risk for dementia [21] . In the chemotherapy order templates that were reviewed, single doses as high as 100 mg of diphenhydramine were included, which raises concern as significant psychomotor impairment has been observed in healthy elderly volunteers with doses higher than 50 mg [22] . Metoclopramide is also listed under the AGS Beers Criteria of medications to avoid for many or most older adults and can cause extrapyramidal effects, including tardive dyskinesia, especially in frail older adults [23, 24] .
Benzodiazepines and antipsychotics are listed under the AGS Beers category of medications to avoid for many or most older adults and older adults with delirium or falls. In general, all benzodiazepines can increase the risk of cognitive impairment, delirium, falls, and fractures in older adults, and more recent initiation is associated with a greater risk of falls [25, 26] . Older adults also have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents [26] . In the NCCN chemotherapy order templates reviewed, the total recommended doses of lorazepam in a 24-h period could be as high as 12 mg, which is concerning as higher total doses of benzodiazepines are associated with a greater risk of falls with injuries [27, 28] . Antipsychotics such as olanzapine can increase the risk of cerebrovascular accident (CVA) [29] , and are associated with a greater rate of cognitive decline and mortality in older adults with dementia [30] . Antipsychotics should also be avoided in older adults with a history of falls or fractures as these agents can cause ataxia, impair psychomotor function, and induce syncope, leading to additional falls [31, 32] .
Corticosteroids and H 2 -receptor antagonists are listed under the category of medications to avoid in older adults with specific diseases or syndromes, such as delirium or falls. Corticosteroids are associated with cognitive impairment and worsening delirium in older adults [33] . The dose of corticosteroids can also impact the incidence of CNS toxicity, with those receiving [ 80 mg of prednisone or equivalent being at the highest risk for developing acute psychiatric reactions [34, 35] . H 2 -receptor Ò and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to http://www.nccn.org [13] ) The NCCN makes no warranties of any kind whatsoever regarding their content, use or application, and disclaims any responsibility for their application or use in any way PIMs potentially inappropriate medications, NCCN National Comprehensive Cancer Network, ECG electrocardiography, AIMS Abnormal Involuntary Movements Scale antagonists are associated with CNS toxicities such as confusion, disorientation, agitation, and hostility, and should be avoided in older adults with delirium [36] . Furthermore, it has been noted that standard doses of H 2 -receptor antagonists may lead to a higher risk of adverse drug events and mortality in older adults as age-related decreases in glomerular filtration rate may decrease excretion of H 2 -receptor antagonists [33, 37] .
Assessing individual risk of severe toxicity from chemotherapy is important for all patients undergoing chemotherapy, but is especially important for older adults who may have significant variability in their health status and functional reserve. Tools to predict the risk of chemotherapy toxicity in older adults have been developed [38, 39] but have not been validated to specifically predict emesis risk and the associated complications in older adults undergoing chemotherapy. Interestingly, there have been data to suggest that older patients are less likely to experience chemotherapy-induced nausea and vomiting compared with younger patients [40] [41] [42] , which may be relevant when selecting antiemetic agents. Development of tools to identify individuals who are at increased risk for treatment-related emesis are needed to better assess the risks and benefits of utilizing PIMs as supportive therapies in older adults undergoing chemotherapy.
There are several limitations to our study. Specifically, we did not evaluate the frequency of all potential PIMs identified by the AGS Beers Criteria that are recommended in the NCCN chemotherapy order templates. The NCCN Guidelines for Older Adult Oncology list of medications commonly used for supportive care that are of concern in older patients [13] provides a more comprehensive list of PIMs that may be encountered in the treatment of older adults with cancer. Additionally, we did not focus on the precise indications for each supportive care medication in the guidelines, which are important considerations when deciding on the risks and benefits of using these medications. In addition, we limited our review to the NCCN chemotherapy order templates pertaining to treatment for hematologic malignancies, and therefore did not include all published NCCN chemotherapy order templates. Another limitation of our study is that there have been updates to the NCCN chemotherapy templates and guidelines since our last review. While newer templates and guidelines have been introduced, the practice patterns reflected in our study still persist and providers should remain vigilant regarding the use of PIMs in supportive care during chemotherapy treatment. Finally, while the medications evaluated are considered PIMs, no prospective studies have evaluated the safety or risk of specific adverse outcomes of these medications when used for supportive care in older adults with cancer.
Based on the findings from this study, we recommend that clinicians consider the risk of PIMs as chemotherapy supportive care in their older patients with hematologic malignancies, and consider incorporation of tools such as the AGS Beers Criteria into their therapeutic decision making. This will help increase awareness and better guide clinicians treating older adults with hematologic cancers on how to minimize toxicities related to supportive therapies.
Conclusion
Potentially inappropriate medications are frequently used as supportive therapy in the treatment of hematologic malignancies. Increasing awareness among healthcare providers of their potential side effects and devising methods to minimize the risks associated with their use is important in improving the management of older adults with hematologic cancers undergoing chemotherapy.
